Baxter International, Inc. (BAX)
| Market Cap | 39.66B |
| Revenue (ttm) | 11.67B |
| Net Income (ttm) | 1.10B |
| Shares Out | 509.00M |
| EPS (ttm) | 2.13 |
| PE Ratio | 36.86 |
| Forward PE | 23.20 |
| Dividend | $0.96 |
| Dividend Yield | 1.22% |
| Trading Day | February 24 |
| Last Price | $78.51 |
| Previous Close | $78.14 |
| Change ($) | 0.37 |
| Change (%) | 0.47% |
| Day's Open | 78.25 |
| Day's Range | 77.48 - 78.67 |
| Day's Volume | 2,503,715 |
| 52-Week Range | 68.50 - 94.36 |
Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.
Baxter (BAX) delivered earnings and revenue surprises of 5.26% and 0.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Baxter International (NYSE:BAX) moved higher by 0.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 1700.00% over the past yea...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter and full year ended December 31...
Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 10th Annual SVB Leerink Global Healthcare Conference on W...
The pandemic is only a temporary setback for this diversified global manufacturer of medical devices.
According to the GuruFocus All-in-One Screener as of Jan. 15, the following Health Care stocks are popular among gurus.
We think that Baxter International currently is a better pick compared to Boston Scientific. BAX stock trades at about 3.6x trailing Revenues, compared to around 5.2x for Boston Scientific.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial resu...
We believe that Baxter stock, a healthcare supply company, is a good buying opportunity at the present time. BAX stock trades near $80 currently and it is, in fact, down 16% from its pre-Covid...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast...
Baxter's (BAX) Vital Edge program enables AdventHealth Tampa to achieve cost savings.
TAMPA, Fla.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, and AdventHealth Tampa today announced that AdventHealth Tampa will realiz...
The MS Global Franchise Fund (Trades, Portfolio), which is part of investment bank Morgan Stanley (NYSE:MS), disclosed its third-quarter portfolio earlier this week.
Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.
Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.
BAX offers a broad portfolio of essential, life-saving healthcare products to treat acute and chronic illnesses. There is no other competitor in the space that competes with BAX in all of thei...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of the Homechoice Cl...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 3rd Annual HealthCONx virtual conference via...
Daniel Loeb (Trades, Portfolio) has revealed his portfolio for the third quarter. During the quarter, the guru added 20 new holdings, including PG&E Corp. (NYSE:PCG) and Microsoft Corp. (NASDA...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash div...
Daniel Loeb (Trades, Portfolio)'s Third Point Management sold shares of the following stocks during the third quarter, which ended on Sept. 30.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today published its first Sustainability Accounting Standards Board (SASB) in...
LONDON--(BUSINESS WIRE)-- #GlobalIntravenousFluidBagsMarket--The Intravenous Fluid Bags Market will grow by $ 667.51 mn during 2020-2024
3 Stocks to Capitalize on Promising Medical Products Industry
Baxter International Inc. (BAX) CEO Jose Almeida on Q3 2020 Results - Earnings Call Transcript
Baxter's (BAX) third-quarter results reflect strong performance across six of its business units.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that it proposes to offer, subject to market conditions and o...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported earnings for the third quarter of 2020 and updated its outlook...
Baxter's (BAX) third-quarter performance is likely to reflect growth in its Acute Therapies business.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking ...
The study, supported by Baxter (BAX) through an investigator-initiated grant, is the first analysis of longitudinal REE in critically ill, mechanically-ventilated COVID-19 patients.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference v...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, supports interim findings of an ongoing prospective study, “Persistent Hypermetabo...
Recent correction and pullback in Baxter's price has turned the tables on valuation, thus presenting an exciting entry point.
Baxter's (BAX) Clinimix and Clinimix E with Higher Protein Injection received FDA approval, which will help clinicians to improve care for critically ill patients.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition, today announced the U.S. Food and Drug Administration (FDA) approval of new form...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc.
The Baxter International Inc. (NYSE:BAX) share price dropped recently. But is it enough of a pullback to justify the interest of investors?
Baxter's (BAX) expanded HDx therapy delivered by Theranova becomes accessible for patients with kidney failure in the United States.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc.
Baxter (BAX) reported earnings 30 days ago. What's next for the stock?
Bullish On Baxter: Cruising Along, Business As Usual; $90 Price Target Set
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc.
Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.
About BAX
Baxter International, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemo... [Read more...]
| Industry Medical Instruments & Supplies | Founded 1931 |
| CEO Jose Almeida | Employees 50,000 |
| Stock Exchange NYSE | Ticker Symbol BAX |
Financial Performance
In 2020, BAX's revenue was $11.67 billion, an increase of 2.74% compared to the previous year's $11.36 billion. Earnings were $1.10 billion, an increase of 10.09%.
Analyst Forecasts
According to 19 analysts, the average rating for BAX stock is "Buy." The 12-month stock price forecast is 92.18, which is an increase of 17.41% from the latest price.